Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,756 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07204548 | The IVO-LUNG Study(IVO Lung) | not yet recruiting | Phase 2 | 63 | Sun Yat-sen UniversityOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT07198321 | A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 450 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 1 | Sep 30, 2025 | clinicaltrials |
| NCT07197853 | Clinical Efficacy and Safety of Microwave Ablation Combined With Huaier Granules in Patients With Inoperable Stage IA Non-Small Cell Lung Cancer: A Prospective, Single-Center, Randomized Controlled Clinical Trial(HAMSTER) | not yet recruiting | Phase 3 | 180 | Xin YeOTHER | 0 | Sep 29, 2025 | clinicaltrials |
| NCT07193160 | Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy | not yet recruiting | Phase 2 | 45 | Fudan UniversityOTHER | 0 | Sep 25, 2025 | clinicaltrials |
| NCT07190027 | Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial | not yet recruiting | Phase 1 / Phase 2 | 246 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 0 | Sep 24, 2025 | clinicaltrials |
| NCT07060950 | Analysis of Circulating Tumor Markers in Blood - ALCINA 5(ALCINA 5) | not yet recruiting | N/A | 620 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT07154368 | JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs. | not yet recruiting | Phase 3 | 207 | Guangzhou JOYO Pharma Co., LtdINDUSTRY | 0 | Sep 19, 2025 | clinicaltrials |
| NCT07182708 | High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC(HOFIBREN) | not yet recruiting | Phase 2 | 62 | Peking University Cancer Hospital & InstituteOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT07179445 | Analysis of Deoxyribonucleic Acid and Ribonucleic Acid Next-Generation Sequencing in Non-Small Cell Lung Cancer Patients Without Pathological Complete Response Following Neoadjuvant Immunotherapy | not yet recruiting | — | 300 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT07177092 | Primary Tumor Resection Plus Osimertinib in Advanced EGFR-mutant Non-small Cell Lung Cancer(SURGAN-TKI) | not yet recruiting | Phase 2 | 118 | Jianxing HeOTHER | 0 | Sep 16, 2025 | clinicaltrials |
| NCT07177105 | Primary Tumor Resection With Sintilimab and Chemotherapy in Advanced NSCLC(SURGAN-ICI) | not yet recruiting | Phase 2 | 118 | Jianxing HeOTHER | 0 | Sep 16, 2025 | clinicaltrials |
| NCT07173244 | A Real-world Study of Adebrelimab-based Combination Regimens in the Treatment of Advanced Solid Tumors | not yet recruiting | — | 300 | Tianjin First Central HospitalOTHER | 0 | Sep 15, 2025 | clinicaltrials |
| NCT07169903 | Segmentectomy vs Lobectomy for 2 - 3cm IASLC Grade 1-2 Lung Adenocarcinoma: A Multi-center RCT(STAR012) | not yet recruiting | Phase 3 | 587 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT07162883 | Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) | not yet recruiting | Phase 3 | 122 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Sep 9, 2025 | clinicaltrials |
| NCT07150598 | Immune-Marker Platform for Patients With Advanced Lung Cancer(IMPALUX) | not yet recruiting | — | 500 | Technische Universität DresdenOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT07158840 | AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment(AGA TKI NSCLC) | not yet recruiting | Phase 2 | 60 | AkesoINDUSTRY | 1 | Sep 8, 2025 | clinicaltrials |
| NCT07159646 | Athletic Intervention After THoracic surgEry for luNg cAncer: a Pilot Study | not yet recruiting | N/A | 10 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT07156604 | Vebreltinib for Neoadjuvant in METex 14 Skipping Mutant Stage IIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC) | not yet recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT07153770 | Bozitinib Combined With Chemotherapy as Radical Treatment for Stage IIA-IIIC MET-Altered Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 34 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Sep 4, 2025 | clinicaltrials |
| NCT07139041 | Iparomlimab and Tuvonralimab Plus Chemotherapy for Inducing Conversion to Resectability in Initially Unresectable Stage III NSCLC | not yet recruiting | Phase 2 | 69 | Chang ChenOTHER | 0 | Aug 24, 2025 | clinicaltrials |
| NCT07134413 | QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC | not yet recruiting | Phase 2 | 77 | Guangdong Association of Clinical TrialsOTHER | 0 | Aug 21, 2025 | clinicaltrials |
| NCT07105176 | HS-IT101 Injection for Advanced NSCLC | not yet recruiting | Phase 1 | 12 | Qingdao Sino-Cell Biomedicine Co., Ltd.INDUSTRY | 1 | Aug 19, 2025 | clinicaltrials |
| NCT07129161 | Iparomlimab and Tuvonralimab Combined With 2 or 4 Cycles of Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC | not yet recruiting | Phase 2 | 66 | Sun Yat-sen UniversityOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT07119190 | A Perioperative Comprehensive Diagnosis and Treatment System for Lung Cancer in the Era of Neoadjuvant Immunotherapy | not yet recruiting | — | 350 | Peking University People's HospitalOTHER | 0 | Aug 12, 2025 | clinicaltrials |
| NCT07110363 | A Clinical Study of BT02 in Treating Patients With Advanced Lung Cancer | not yet recruiting | Phase 1 | 58 | Biotroy TherapeuticsINDUSTRY | 0 | Aug 7, 2025 | clinicaltrials |
| NCT06711770 | Effect of G-CSF on MDSC and Cancer Stem-cells Interactions in Non-small Cell Lung Cancers (CIRCUIT)(CIRCUIT) | not yet recruiting | N/A | 30 | University Hospital, BordeauxOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT07093762 | Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC | not yet recruiting | — | 35 | Fuzhou General HospitalOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT07063329 | Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive | not yet recruiting | Phase 1 / Phase 2 | 108 | Avistone Pharmaceutical（Ningbo）Co., LTD.INDUSTRY | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07086326 | A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC(NEOINSPIRE) | not yet recruiting | Phase 2 | 164 | Yang Fan, MDOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT06951399 | Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 30 | Rabin Medical CenterOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT07076914 | Prophylactic Proton Pump Inhibition for Esophageal Protection in Lung Radiation Therapy(PPI-PROTECT) | not yet recruiting | Phase 2 | 58 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT05909137 | Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer | not yet recruiting | — | 60 | Xinqiao Hospital of ChongqingOTHER | 0 | Jul 14, 2025 | clinicaltrials |
| NCT07051928 | Study of Atezolizumab in Advanced Non-oncogene-addicted NSCLC With PD-L1 ≥50%, Including Longitudinal c-FLIP Assessment in Monocytic MDSCs.(FLIP-IMMUNO) | not yet recruiting | — | 107 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT06974097 | Tumor Associated Neutrophils as a Biomarker of Chemo-immunotherapy Response in Locally Advanced Non-small Cell Lung Cancer : a Model Based on Neoadjuvant Strategy(NEO-TAN) | not yet recruiting | — | 72 | University Hospital, MontpellierOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT07043907 | PANK-003 Cell Injection Combined With Standard Adjuvant Chemotherapy After Surgery in Patients With Stage IIIA NSCLC | not yet recruiting | Phase 2 | 115 | Shenzhen Celconta Life Science Co., Ltd.INDUSTRY | 0 | Jul 1, 2025 | clinicaltrials |
| NCT06977828 | A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC | not yet recruiting | Phase 2 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT07034365 | Risk and Prognosis of Brain Metastasis in Non-Small Cell Lung Cancer | not yet recruiting | — | 2,000 | Fudan UniversityOTHER | 0 | Jun 29, 2025 | clinicaltrials |
| NCT06829641 | Clinical Outcomes of Tislelizumab Combined With Chemotherapy as Induction Therapy in Stage III (cTNM-IIIB/IIIC) NSCLC | not yet recruiting | — | 200 | West China HospitalOTHER | 0 | Jun 27, 2025 | clinicaltrials |
| NCT07038460 | A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC(NEO-LISI) | not yet recruiting | Phase 2 | 134 | Wen-zhao ZHONGOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT07035392 | Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC | not yet recruiting | Phase 2 | 32 | Zhangzhou Municipal HospitalOTHER | 0 | Jun 25, 2025 | clinicaltrials |
| NCT07035444 | Enteral Nutrition With L-Carnitine for Cachexia in Non-Small Cell Lung Cancer | not yet recruiting | N/A | 126 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT07036185 | A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors | not yet recruiting | Phase 1 | 66 | Shanghai Bao Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 25, 2025 | clinicaltrials |
| NCT07031154 | A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 43 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT07014215 | PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy | not yet recruiting | Phase 2 | 52 | Anhui Provincial Cancer HospitalOTHER | 0 | Jun 10, 2025 | clinicaltrials |
| NCT07009925 | Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC. | not yet recruiting | Phase 2 | 38 | Jiangsu Cancer Institute & HospitalOTHER | 0 | Jun 8, 2025 | clinicaltrials |
| NCT06998719 | Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC(ACCESS) | not yet recruiting | Phase 2 | 80 | Bi NanOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT06986291 | Radiation-induced Toxicity of the Heart(CorTox) | not yet recruiting | N/A | 325 | Technische Universität DresdenOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT06970782 | Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure(KYLIN-3) | not yet recruiting | Phase 3 | 278 | Avistone Biotechnology Co., Ltd.INDUSTRY | 0 | May 21, 2025 | clinicaltrials |
| NCT06979661 | Trial of ctDNA of Guidance to Determine PostOperative Radiation Therapy(PORT) | not yet recruiting | Early Phase 1 | 25 | Rutgers, The State University of New JerseyOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT06971406 | High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastasis(FLAME-1) | not yet recruiting | Phase 2 | 100 | Qiming WangOTHER_GOV | 0 | May 14, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Oct 2, 2025source: clinicaltrials